Publications in collaboration with researchers from Ibaraki Prefectural Central Hospital (2)

2023

  1. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578

2018

  1. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    New England Journal of Medicine, Vol. 379, Núm. 19, pp. 1811-1822